Badanie porównujące biktegrawir/lenakapawir z obecną terapią u osób zakażonych wirusem HIV-1, które są skutecznie leczone lekiem Biktarvy (ARTISTRY-2)
Faza 3. Wieloośrodkowe, podwójnie ślepe, randomizowane, kontrolowane substancją czynną badanie oceniające bezpieczeństwo i skuteczność biktegrawiru/lenakapawiru w porównaniu z lekiem Biktarvy® (biktegrawir/emtrycytabina/alafenamid tenofowiru) u osób z obniżoną wirusologią z HIV-1
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH) who are successfully treated with B/F/TAF (virologically suppressed).
The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) FDC tablets versus continuing on B/F/TAF (50/200/25 mg) FDC tablets in virologically suppressed PWH.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Buenos Aires, Argentyna, C1141ACG
- Helios Salud S.A.
-
Buenos Aires, Argentyna, C1202ABB
- Fundacion Huesped
-
Santa Fe, Argentyna, S2000PBJ,
- Instituto CAICI SRL
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2011
- Taylor Square Private Clinic
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Alfred Hospital(Alfred Health)
-
South Yarra, Victoria, Australia, 3141
- Prahran Market Clinic
-
-
-
-
-
Badalona Barcelona, Hiszpania, 8916
- Hospital Universitario Germans Trias i Pujol
-
Barcelona, Hiszpania, 08036
- Hospital Clinic de Barcelona
-
Madrid, Hiszpania, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Hiszpania, 28046
- Hospital Universitario La Paz - PPDS
-
Seville, Hiszpania, 4103
- Hospital Universitario Virgen del Rocio - PPDS
-
Valencia, Hiszpania, 46014
- Consorcio Hospital General Universitario de Valencia
-
-
-
-
-
Aichi, Japonia, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Osaka, Japonia, 540-0006
- National Hospital Organization Osaka National Hospital
-
Tokyo, Japonia, 162-0052
- Center Hospital of the National Center for Global Health and Medicine
-
-
-
-
-
Decarie Montreal, Kanada, H4A 3J1
- Chronic Viral Illness Service/McGill University Health Centre (MUHC)
-
Montreal, Kanada, H2L 4P9
- Clinique Médicale l'Actuel
-
Ottawa, Kanada, K1H 8L6
- The Ottawa Hospital - General Campus
-
Regina, Kanada, S4P 0W5
- Regina General Hospital
-
Vancouver, Kanada, V6Z1Y6
- St. Paul's Hospital, John Ruedy Clinic-Immunodeficiency Clinic (JRC-IDC)
-
Victoria, Kanada, V8W 1M8
- Cool Aid Community Health Centre
-
-
-
-
-
Daegu, Korea Południowa, 41944
- Kyungpook National University Hospital
-
Seoul, Korea Południowa, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Korea Południowa, *04564
- National Medical Center
-
Seoul, Korea Południowa, 137-701
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
-
-
-
Mexico City, Meksyk, 6170
- ProcliniQ Investigacion Clinica Toriello Guerra, Tlalpan
-
Mérida, Meksyk, 97070
- Unidad de Atencion Medica e Investigacion en Salud
-
-
-
-
-
Aachen, Niemcy, 52062
- Praxis Dr. Knechten
-
Berlin, Niemcy, 10117
- Novopraxis Berlin
-
Cologne, Niemcy, 50668
- Praxis am Ebertplatz
-
Frankfurt, Niemcy, 60590
- Universitätsklinikum Frankfurt
-
Hamburg, Niemcy, 20246
- Universitätsklinikum Hamburg Eppendorf
-
Munich, Niemcy, 80336
- LMU Klinikum der Universität
-
München, Niemcy, 81675
- Klinikum rechts der Isar der Technischen Universitaet Muenchen
-
-
-
-
PR
-
San Juan, PR, Portoryko, 00935
- Proyecto ACTU
-
San Juan, PR, Portoryko, 00909
- HOPE Clinical Research
-
-
-
-
-
Santo Domingo, Republika Dominikany
- Instituto Dominicano de Estudios Virologicos - IDEV
-
-
-
-
Arizona
-
Phoenix, Arizona, Stany Zjednoczone, 85015
- Pueblo Family Physicians
-
-
California
-
Berkeley, California, Stany Zjednoczone, 48072
- Be Well Medical Center
-
Beverly Hills, California, Stany Zjednoczone, 90211
- Pacific Oaks Medical Group
-
Los Angeles, California, Stany Zjednoczone, 90036
- Ruane Clinical Research Group Inc.
-
Oakland, California, Stany Zjednoczone, 94609
- Alta Bates Summit Medical Center, Summit Campus, East Bay Advanced Care
-
Palm Springs, California, Stany Zjednoczone, 92262
- BIOS Clinical Research
-
San Diego, California, Stany Zjednoczone, 92103
- UCSD Anti Viral Research Centre (AVRC)
-
Torrance, California, Stany Zjednoczone, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
West Hollywood, California, Stany Zjednoczone, 90046
- Mills Clinical Research
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80204
- Public Health Institute at Denver Health
-
-
Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06510
- Yale University School of Medicine (study visits)
-
-
Florida
-
DeLand, Florida, Stany Zjednoczone, 32720
- Midland Florida Infectious Diseases Specialists, PL - Orange City
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33308
- Therafirst Medical Center
-
Fort Lauderdale, Florida, Stany Zjednoczone, 33316
- CAN Community Health
-
Ft. Pierce, Florida, Stany Zjednoczone, 34982
- Midway Immunology and Research Center
-
Miami, Florida, Stany Zjednoczone, 33133
- AIDS Healthcare Foundation - The Kinder Medical Group
-
Miami, Florida, Stany Zjednoczone, 33136
- Schiff Center for liver Diseases/University of Miami
-
Miami Lakes, Florida, Stany Zjednoczone, 33016
- Floridian Clinical Research
-
Orlando, Florida, Stany Zjednoczone, 32803
- Orlando Immunology Center
-
Orlando, Florida, Stany Zjednoczone, 32806
- Bliss Healthcare
-
Pensacola, Florida, Stany Zjednoczone, 32503
- AHF Pensacola
-
Sarasota, Florida, Stany Zjednoczone, 34237
- CAN community Health
-
West Palm Beach, Florida, Stany Zjednoczone, 33407
- Triple O Research Institute, P.A.
-
-
Georgia
-
Decatur, Georgia, Stany Zjednoczone, 30033
- Infectious Disease Specialists of Atlanta
-
Macon, Georgia, Stany Zjednoczone, 31201
- Mercer University, Department of Internal Medicine
-
-
Massachusetts
-
Springfield, Massachusetts, Stany Zjednoczone, 01105
- Claudia T Martorell MD LLC dba The Research Institute
-
-
Michigan
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Health
-
-
Missouri
-
Kansas City, Missouri, Stany Zjednoczone, 64111
- KC Care health Center
-
St Louis, Missouri, Stany Zjednoczone, 63139
- Southampton Community Healthcare, Inc.
-
-
New Jersey
-
Hillsborough, New Jersey, Stany Zjednoczone, 08844
- ID Care, LLC
-
Newark, New Jersey, Stany Zjednoczone, 07102
- Saint Michael's Medical Center
-
Newark, New Jersey, Stany Zjednoczone, 07103
- New Jersey Medical School - Clinical Research Center
-
Somers Point, New Jersey, Stany Zjednoczone, 08244
- South Jersey Infectious Disease
-
-
New Mexico
-
Santa Fe, New Mexico, Stany Zjednoczone, 87505
- AXCES Research Group, LLC
-
-
New York
-
Flushing, New York, Stany Zjednoczone, 11355
- New York-Presbyterian Queens
-
The Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Greenville, North Carolina, Stany Zjednoczone, 27858
- The Brody School of Medicine at East Carolina University , ECU Adult Specialty Care
-
Huntersville, North Carolina, Stany Zjednoczone, 28078
- Rosedale Health and Wellness
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Philadelphia FIGHT Community Health Centers
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina (MUSC) Research Nexus
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78705
- Central Texas Clinical Research
-
Bellaire, Texas, Stany Zjednoczone, 77401
- St Hope Foundation, Inc.
-
Dallas, Texas, Stany Zjednoczone, 75208
- AIDS Arms, Inc. DBA Prism Health North Texas
-
Dallas, Texas, Stany Zjednoczone, 75246
- North Texas Infectious Diseases Consultants, PA
-
El Paso, Texas, Stany Zjednoczone, 79902
- AXCES Research Group, LLC
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- Texas Centers for Infectious Disease Associates
-
Houston, Texas, Stany Zjednoczone, 77098
- The Crofoot research Center, INC.
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84102
- AXCES Research Group, LLC
-
-
Virginia
-
Annandale, Virginia, Stany Zjednoczone, 22003
- Clinical Alliance For Research & Education - Infectious Diseases. LLC (CARE-ID)
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98104
- Peter Shalit MD
-
Tacoma, Washington, Stany Zjednoczone, 98405
- Community Health care
-
-
-
-
-
Kaohsiung City, Tajwan, 81362
- Kaohsiung Veterans General Hospital
-
Kaohsiung City, Tajwan, 80756
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taipei, Tajwan, 100
- National Taiwan University Hospital
-
Taoyuan City, Tajwan, 33004
- Taoyuan General Hospital, Ministry of Health and Welfare
-
-
-
-
-
Brescia, Włochy, 25123
- ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia - INCIPIT - PIN
-
Foggia, Włochy, 71122
- Azienda Ospedaliero Universitaria Ospedali Riuniti (Policlinico di Foggia)
-
Milan, Włochy, 20127
- IRCCS Ospedale San Raffaele
-
Monza, Włochy, 20090
- Fondazione IRCCS San Gerardo dei Tintori - ASST di Monza - A. O. San Gerardo
-
Pavia, Włochy, 27100
- Fondazione IRCCS Policlinico San Matteo di Pavia
-
Roma, Włochy, 00168
- Fondazione Policlinico Universitario A Gemelli-Rome
-
Roma, Włochy, 00149
- Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS
-
-
-
-
-
Liverpool, Zjednoczone Królestwo, L7 8XP
- Liverpool University Hospitals NHS Foundation Trust, Royal Liverpool Hospital
-
London, Zjednoczone Królestwo, WC1E 6JB
- Mortimer Market Centre
-
London, Zjednoczone Królestwo, SE5 9RS
- King's College Hospital, Weston Education Centre
-
London, Zjednoczone Królestwo, SW109NH
- Chelsea and Westminster Hospital NHS Foundation Trust, St Stephen's Centre, Chelsea and Westminster Hospital
-
London, Zjednoczone Królestwo, W2 1NY
- St Mary's Hospital - PPDS
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Key Inclusion Criteria:
- Currently receiving B/F/TAF for at least 6 months prior to screening.
- If plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid (RNA) measurements in the last 6 months prior to screening are available, all levels must be < 50 copies/mL.
- At least one documented HIV-1 RNA level measured between 6 and 12 months (± 2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL.
- Plasma HIV-1 RNA levels < 50 copies/mL at screening.
- No documented or suspected resistance to BIC (including integrase strand-transfer inhibitor resistant (INSTI-R) mutations T66A/I/K, E92G/Q, G118R, F121Y, Y143C/H/R, S147G, Q148H/K/R, N155H/S, or R263K in the integrase gene).
- No documented or suspected resistance to tenofovir alafenamide (TAF) (TAF; mutations K65R, K65N, K70E, Q151M or T69 insertion, or ≥ 3 of the following thymidine analog mutations [M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R] in the reverse transcriptase gene).
- Estimated glomerular filtration rate ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance.
Key Exclusion Criteria:
-
Positive serum pregnancy test or pregnant at screening or a positive pregnancy test prior to Day 1 randomization.
-
Breastfeeding (nursing).
-
Prior use of, or exposure to, LEN.
-
Active, serious infections (other than HIV-1) requiring parenteral therapy < 30 days prior to randomization.
-
Active tuberculosis infection.
-
Acute hepatitis < 30 days before randomization.
-
Chronic hepatitis B virus (HBV) infection, as determined by either:
- Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
- Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
-
Known hypersensitivity to the study drug, its metabolites, or any formulation excipient.
-
History of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
-
Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant as determined by the investigator.
-
Active malignancy requiring acute systemic therapy.
-
Any of the following laboratory values at screening:
- Alanine aminotransferase > 5 × upper limit of normal (ULN).
- Direct bilirubin > 1.5 × ULN.
- Platelets < 50,000/mm^3.
- Hemoglobin < 8.0 g/dL.
-
Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.
-
Participation or planned participation in any other clinical study (including observational studies) without prior approval from the sponsor.
-
Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Blinded Phase: Treatment Group 1: BIC/LEN 75/50 mg
Participants will switch from bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed-dose combination (FDC) tablets to bictegravir/lenacapavir (BIC/LEN) 75/50 mg FDC tablets + placebo-to-match (PTM) B/F/TAF tablets, administered orally, once daily up to 48 weeks. Participants will also receive a 2-day oral pharmacokinetic (PK) loading dose of LEN 600 mg on Days 1 and 2, in addition to the daily doses of BIC/LEN 75/50 mg and PTM B/F/TAF tablets starting on Day 1. At the end of blinded treatment (EBT) participants will enter the open label (OL) phase and continue to receive BIC/LEN 75 mg/50 mg FDC tablets through at least 48 weeks in the OL phase. At the OL Week 48, participants will be given an option to continue to receive BIC/LEN FDC tablets. |
Tablets administered orally without regard to food
Inne nazwy:
Tablets administered orally without regard to food
Inne nazwy:
Tablets administered orally without regard to food |
|
Aktywny komparator: Blinded Phase: Treatment Group 2: B/F/TAF 50/200/25 mg
Participants will continue with their B/F/TAF 50/200/25 mg tablets and start PTM BIC/LEN tablets on Day 1 administered orally, once daily up to 48 weeks. Participants will receive PTM oral LEN PK loading tablets for 2 days (2 PTM LEN tablets on Day 1 and on Day 2). Participants who complete the EBT will be given an option to enter the OL phase to receive BIC/LEN FDC tablets. |
Tablets administered orally without regard to food
Inne nazwy:
Tablets administered orally without regard to food Tablets administered orally without regard to food |
|
Eksperymentalny: Open-label Phase: BIC/LEN 75/50mg
Participants from Treatment Group 1 will receive BIC/LEN FDC tablets through at least OL Week 48. At the OL Week 48 visit, participants from Treatment Group 1 will be given the option to continue to receive BIC/LEN FDC tablets. Participants in Treatment Group 2 who complete the EBT visit will be given the option to enter the OL phase to receive BIC/LEN FDC tablets. Participants from Treatment Group 2 who enter the OL phase will also receive a 2-day oral loading dose of LEN 600 mg (2 × 300 mg LEN on Day 1 and on Day 2). All participants who enter the OL phase may continue to receive BIC/LEN FDC tablets daily until study drug is available or until Gilead Sciences (Gilead) elects to discontinue the study. |
Tablets administered orally without regard to food
Inne nazwy:
Tablets administered orally without regard to food
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 48 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm
Ramy czasowe: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA≥ 50 copies/mL in the Week 48 analysis window, or who did not have on-treatment HIV-1 RNA data in the Week 48 analysis window and participants who discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or who discontinued study drug prior to or in the Week 48 analysis window due to reasons other than adverse event (AE), death, or lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL were included. The Week 48 window was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Determined by the US FDA-Defined Snapshot Algorithm
Ramy czasowe: Week 48
|
Participants who had the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window were included. The Week 48 window for snapshot algorithm was between Days 295 and 378 (inclusively). Percentages were rounded off. |
Week 48
|
|
Change From Baseline in Clusters of Differentiation 4 (CD4) Cell Count at Week 48
Ramy czasowe: Baseline, Week 48
|
Baseline, Week 48
|
|
|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) Through Week 48
Ramy czasowe: First dose date up to Week 48
|
An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. TEAEs were defined as any AE that begins on or after the date of first dose of study drug up to the date of last dose of study drug plus 60 days (for BIC/LEN FDC, Treatment Group 1) or 30 days (for B/F/TAF, Treatment Group 2) or any AE leading to study drug discontinuation. Percentages were rounded off. |
First dose date up to Week 48
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 96 as Determined by the US FDA-Defined Snapshot Algorithm
Ramy czasowe: Week 96
|
Week 96
|
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96 as Determined by US FDA-Defined Snapshot Algorithm
Ramy czasowe: Week 96
|
Week 96
|
|
|
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 96
Ramy czasowe: Week 96
|
Week 96
|
|
|
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 96
Ramy czasowe: First dose date up to Week 96
|
First dose date up to Week 96
|
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 144 as Determined by the US FDA-Defined Snapshot Algorithm
Ramy czasowe: Week 144
|
Week 144
|
|
|
Treatment Group 1: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 144 as Determined by US FDA-Defined Snapshot Algorithm
Ramy czasowe: Week 144
|
Week 144
|
|
|
Treatment Group 1: Change From Baseline in CD4 Cell Count at Week 144
Ramy czasowe: Week 144
|
Week 144
|
|
|
Treatment Group 1: Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 144
Ramy czasowe: First dose date up to Week 144
|
First dose date up to Week 144
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Dyrektor Studium: Gilead Study Director, Gilead Sciences
Publikacje i pomocne linki
Publikacje ogólne
- Arora P, Hindman JT, West S, Ling J, Palaparthy R, Marathe DD. The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study. Antimicrob Agents Chemother. 2026 Jan 7;70(1):e0078125. doi: 10.1128/aac.00781-25. Epub 2025 Nov 28.
- Meissner EG, Ramgopal M, Ruane PJ, Sanchez W, Crofoot G, Routy JP, Brinson C, DeJesus E, Martorell CT, Tellez M, Yokomaku Y, O'Reilly M, Lupo S, Schellberg S, Lezama-Mora JI, Chin B, Aizen K, D'Antoni ML, Huang H, Mponponsuo K, Montezuma-Rusca JM, Sklar P, Rhee M, Hung CC; ARTISTRY-2 Study Group. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet HIV. 2026 Aug;13(8):e538-e547. doi: 10.1016/S2352-3018(26)00078-0. Epub 2026 May 6.
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- GS-US-621-6290
- 2023-510022-33 (Inny identyfikator: European Medicines Agency)
- jRCT2051240046 (Identyfikator rejestru: Japan Registry)
- 2023 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .